Physician profile
Lisa Rose Centilli
NPI 1033417522
$1,849.75
in general payments reported to CMS, 2019-2025
26 companies · $341 in 2025
The $341 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $82.51 · 2020: $226 · 2021: $202 · 2022: $176 · 2023: $523 · 2024: $300 · 2025: $341.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,164.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $329.49 | 2020-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $202.49 | 2021-2023 | Vraylar, Qulipta |
| Dexcom, INC. | $180.72 | 2023-2025 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $150.57 | 2020-2021 | |
| Pfizer INC. | $125.17 | 2020-2025 | |
| Glaxosmithkline, LLC. | $104.75 | 2021-2025 | Shingrix, Arexvy |
| Amgen INC. | $92.69 | 2019-2023 | Repatha, Otezla |
| Merz North America, INC. | $80.88 | 2023 | |
| Janssen Pharmaceuticals, INC | $77.73 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $76.68 | 2021-2024 | Gvoke Hypopen, Recorlev |
| Astrazeneca Pharmaceuticals LP | $52.31 | 2020-2025 | Farxiga, Airsupra |
| Daiichi Sankyo INC. | $47.02 | 2022-2023 | Injectafer |
| Gilead Sciences, INC. | $38.90 | 2020 | |
| Abbott Laboratories | $38.31 | 2025 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $37.70 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $36.68 | 2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $25.46 | 2020 | |
| Sanofi-Aventis U.S. LLC | $22.80 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.41 | 2025 | Xifaxan |
| Ardelyx, INC. | $20.05 | 2024 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $17.73 | 2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $17.49 | 2024 | |
| Lilly USA, LLC | $14.67 | 2022 | |
| Exact Sciences Corporation | $13.70 | 2025 | Cologuard Collection Kit |
| Currax Pharmaceuticals LLC | $13.25 | 2021 | |
| Allergan, INC. | $12.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Centilli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.